{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:16:26Z","timestamp":1740107786022,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00774-019-01031-x","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T08:02:43Z","timestamp":1565942563000},"page":"86-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II\/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis"],"prefix":"10.1007","volume":"38","author":[{"given":"Satoshi","family":"Soen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruki","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitsugu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"1031_CR1","first-page":"435","volume":"7","author":"S Das","year":"2013","unstructured":"Das S, Crockett JC (2013) Osteoporosis\u2014a current view of pharmacological prevention and treatment. Drug Des Dev Ther 7:435\u2013448","journal-title":"Drug Des Dev Ther"},{"key":"1031_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.7326\/M14-0317","volume":"161","author":"CJ Crandall","year":"2014","unstructured":"Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711\u2013723","journal-title":"Ann Intern Med"},{"key":"1031_CR3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1007\/s12325-016-0360-3","volume":"33","author":"I Goldshtein","year":"2016","unstructured":"Goldshtein I, Rouach V, Shamir-Stein N, Yu J, Chodick G (2016) Role of side effects, physician involvement, and patient perception in non-adherence with oral bisphosphonates. Adv Ther 33:1374\u20131384","journal-title":"Adv Ther"},{"key":"1031_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1046\/j.1365-2125.1999.00035.x","volume":"48","author":"DY Mitchell","year":"1999","unstructured":"Mitchell DY, Heise MA, Pallone KA, Clay ME, Nesbitt JD, Russell DA, Melson CW (1999) The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 48:536\u2013542","journal-title":"Br J Clin Pharmacol"},{"key":"1031_CR5","unstructured":"Warner Chilcott Company LLC (2015) ACTONEL\u00ae (risedronate sodium) tablets, United States prescribing information. \nhttp:\/\/www.allergan.com\/assets\/pdf\/actonel_pi"},{"key":"1031_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","volume":"48","author":"D Kendler","year":"2004","unstructured":"Kendler D, Kung AW, Fuleihan G, Gonzalez Gonzalez JG, Gaines KA, Verbruggen N, Melton ME (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243\u2013251","journal-title":"Maturitas"},{"key":"1031_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11657-015-0231-6","volume":"10","author":"H Kishimoto","year":"2015","unstructured":"Kishimoto H, Maehara M (2015) Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos 10:231","journal-title":"Arch Osteoporos"},{"key":"1031_CR8","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","volume":"24","author":"JA Simon","year":"2002","unstructured":"Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70\u00a0mg versus once-daily alendronate 10\u00a0mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871\u20131886","journal-title":"Clin Ther"},{"key":"1031_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1532-5415.2006.00696.x","volume":"54","author":"S Agrawal","year":"2006","unstructured":"Agrawal S, Krueger DC, Engelke JA, Nest LJ, Krause PF, Drinka PJ, Binkley NC (2006) Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc 54:790\u2013795","journal-title":"J Am Geriatr Soc"},{"key":"1031_CR10","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00198-009-0893-2","volume":"20","author":"DL Kendler","year":"2009","unstructured":"Kendler DL, Ringe JD, Ste-Marie LG, Vrijens B, Taylor EB, Delmas PD (2009) Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int 20:1895\u20131902","journal-title":"Osteoporos Int"},{"key":"1031_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00774-003-0459-x","volume":"22","author":"Y Ogura","year":"2004","unstructured":"Ogura Y, Gonsho A, Cyong JC, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption. J Bone Miner Metab 22:120\u2013126","journal-title":"J Bone Miner Metab"},{"key":"1031_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/IJWH.S18209","volume":"4","author":"P Kinov","year":"2012","unstructured":"Kinov P, Boyanov M (2012) Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health 4:167\u2013174","journal-title":"Int J Womens Health"},{"key":"1031_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00002512-200724010-00003","volume":"24","author":"A Papaioannou","year":"2007","unstructured":"Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24:37\u201355","journal-title":"Drugs Aging"},{"key":"1031_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/TCRM.S52291","volume":"9","author":"M Pazianas","year":"2013","unstructured":"Pazianas M, Abrahamsen B, Ferrari S, Russell RG (2013) Eliminating the need for fasting with oral administration of bisphosphonates. Ther Clin Risk Manag 9:395\u2013402","journal-title":"Ther Clin Risk Manag"},{"key":"1031_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00198-011-1791-y","volume":"23","author":"MR McClung","year":"2012","unstructured":"McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR (2012) Efficacy and safety of a novel delayed-release risedronate 35\u00a0mg once-a-week tablet. Osteoporos Int 23:267\u2013276","journal-title":"Osteoporos Int"},{"key":"1031_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00198-012-2175-7","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR (2013) Treatment of postmenopausal osteoporosis with delayed-release risedronate 35\u00a0mg weekly for 2 years. Osteoporos Int 24:301\u2013310","journal-title":"Osteoporos Int"},{"key":"1031_CR17","unstructured":"Warner Chilcott Company LLC (2015) ATELVIA\u00ae (risedronate sodium) delayed-release tablets, United States prescribing information. \nhttp:\/\/www.allergan.com\/assets\/pdf\/atelvia_pi"},{"key":"1031_CR18","doi-asserted-by":"crossref","unstructured":"Takeda Japan (2017) Phase 1 CPH-401 study, unpublished results","DOI":"10.1299\/jsmeyamanashi.2017.401"},{"key":"1031_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257","journal-title":"J Bone Miner Metab"},{"key":"1031_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bone.2013.10.017","volume":"59","author":"H Hagino","year":"2014","unstructured":"Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T (2014) Efficacy, tolerability and safety of once-monthly administration of 75\u00a0mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5\u00a0mg once-daily dosage regimen. Bone 59:44\u201352","journal-title":"Bone"},{"key":"1031_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2125.2008.03178.x","volume":"66","author":"J Blouin","year":"2008","unstructured":"Blouin J, Dragomir A, Moride Y, Ste-Marie LG, Fernandes JC, Perreault S (2008) Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol 66:117\u2013127","journal-title":"Br J Clin Pharmacol"},{"key":"1031_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40258-013-0078-1","volume":"12","author":"Y Mikyas","year":"2014","unstructured":"Mikyas Y, Agodoa I, Yurgin N (2014) A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men. Appl Health Econ Health Policy 12:267\u2013277","journal-title":"Appl Health Econ Health Policy"},{"key":"1031_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-010-1274-6","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22:21\u201326","journal-title":"Osteoporos Int"},{"key":"1031_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1586\/14737167.2016.1171145","volume":"16","author":"G Chodick","year":"2016","unstructured":"Chodick G, Moser SS, Goldshtein I (2016) Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost. Expert Rev Pharmacoecon Outcomes Res 16:359\u2013370","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1031_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/CIA.S2134","volume":"3","author":"O Bock","year":"2008","unstructured":"Bock O, Felsenberg D (2008) Bisphosphonates in the management of postmenopausal osteoporosis\u2013optimizing efficacy in clinical practice. Clin Interv Aging 3:279\u2013297","journal-title":"Clin Interv Aging"},{"key":"1031_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223\u2013231","journal-title":"Osteoporos Int"},{"key":"1031_CR27","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s001980200135","volume":"13","author":"M Fukunaga","year":"2002","unstructured":"Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971\u2013979","journal-title":"Osteoporos Int"},{"key":"1031_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00774-006-0706-z","volume":"24","author":"H Kishimoto","year":"2006","unstructured":"Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y (2006) Efficacy and tolerability of once-weekly administration of 17.5\u00a0mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405\u2013413","journal-title":"J Bone Miner Metab"},{"key":"1031_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00774-003-0458-y","volume":"22","author":"Y Ogura","year":"2004","unstructured":"Ogura Y, Gonsho A, Cyong JC, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 22:111\u2013119","journal-title":"J Bone Miner Metab"},{"key":"1031_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1592\/phco.2006.26.1.104","volume":"26","author":"G Divittorio","year":"2006","unstructured":"Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB (2006) Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy 26:104\u2013114","journal-title":"Pharmacotherapy"},{"key":"1031_CR31","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research (2010) Risedronate sodium\u2014clinical pharmacology and biopharmaceutics reviews (application number: 022560Orig1s000). \nhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022560orig1s000clinpharmr.pdf"},{"key":"1031_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","volume":"84","author":"KA Kennel","year":"2009","unstructured":"Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84:632\u2013637","journal-title":"Mayo Clin Proc"},{"key":"1031_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40261-012-0041-1","volume":"33","author":"P Sieber","year":"2013","unstructured":"Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C (2013) Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clin Drug Investig 33:117\u2013122","journal-title":"Clin Drug Investig"},{"key":"1031_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2165\/00002018-200730090-00003","volume":"30","author":"W Strampel","year":"2007","unstructured":"Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755\u2013763","journal-title":"Drug Saf"},{"key":"1031_CR35","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s00198-015-3175-1","volume":"26","author":"T Nakamura","year":"2015","unstructured":"Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H (2015) Clinical efficacy and safety of monthly oral ibandronate 100\u00a0mg versus monthly intravenous ibandronate 1\u00a0mg in Japanese patients with primary osteoporosis. Osteoporos Int 26:2685\u20132693","journal-title":"Osteoporos Int"},{"key":"1031_CR36","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315\u20131322","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-019-01031-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-019-01031-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-019-01031-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T23:48:26Z","timestamp":1597448906000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-019-01031-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1007\/s00774-019-01031-x","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"type":"print","value":"0914-8779"},{"type":"electronic","value":"1435-5604"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"27 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.S. has received grants\/research support from Daiichi-Sankyo, Eisai, and Takeda; and is a member of speaker\u2019s bureaus for Asahi Kasei, Astellas Pharma, Chugai, Daiichi-Sankyo, Eisai, Merck Sharp & Dohme, Ono, Pfizer, Takeda, and Teijin Pharma. H.K. has received consulting fees from Asahi Kasei Pharma, Daiichi-Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan. H.H. has received grants\/research support or lecture fees from Asahi Kasei Pharma, Astellas Pharma, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly Japan, Mitsubishi Tanabe, Merck Sharp & Dohme, Ono, Pfizer, Taisho Toyama Pharmaceutical, Takeda, and Teijin Pharma. T.So. has received research grants from Asahi Kasei Pharma, Astellas Pharma, Daiichi-Sankyo, Pfizer, Taisho Toyama Pharmaceutical, Takeda, and Teijin Pharma; and has received consulting fees from Daiichi-Sankyo and Takeda. H.O. is an employee of EA Pharma. T.F. and E.S. are employees of Takeda Pharmaceutical. S.T. has been a consultant and received honoraria from Eisai, given expert testimony for Takeda Pharmaceutical and EA Pharma, undertaken contracted research for EA Pharma, and received endowments from Takeda Pharmaceutical. T.Su. has received research grants from Astellas Pharma, Eisai, Daiichi-Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan as well as consulting and\/or lecture fees from Asahi Kasei Pharma and Daiichi-Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients provided written, informed consent. Trial registration: ClinicalTrials.gov number NCT02063854.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}